Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study.

SAGE Open Med · 2018 · PMC6299310 · PMID 30574306

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The p-values were all highly significant, suggesting that patients’ perception of muscle strength and fatigability improvement was concordant with that of the evaluating neurologists.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.